Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGA: NFC-1 in adolescents with ADHD and mGluR genetic disorders
NCT02777931Phase 3Completed
- Sponsor
- Avalo Therapeutics
- Start
- Jun 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fasoracetam in attention deficit hyperactivity disorder (ADHD), sponsored by Avalo Therapeutics. Started Jun 2016; status: completed.
02
Drugs
fasoracetam
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02777931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777931.